These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33367961)

  • 21. Performance comparison of first-order conditional estimation with interaction and Bayesian estimation methods for estimating the population parameters and its distribution from data sets with a low number of subjects.
    Pradhan S; Song B; Lee J; Chae JW; Kim KI; Back HM; Han N; Kwon KI; Yun HY
    BMC Med Res Methodol; 2017 Dec; 17(1):154. PubMed ID: 29191177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study.
    Park SM; Lee J; Seong SJ; Park JG; Gwon MR; Lim MS; Lee HW; Yoon YR; Yang DH; Kwon KI; Han S
    BMC Pharmacol Toxicol; 2014 Dec; 15():75. PubMed ID: 25534747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity.
    Liu F; Walters SJ; Julious SA
    BMC Med Res Methodol; 2017 Oct; 17(1):149. PubMed ID: 28969588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: application to moxonidine.
    Trocóniz IF; de Alwis DP; Tillmann C; Callies S; Mitchell M; Schaefer HG
    Clin Pharmacol Ther; 2000 Jul; 68(1):18-27. PubMed ID: 10945312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population Pharmacokinetic-Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats.
    Kobuchi S; Ito Y; Sakaeda T
    Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):707-718. PubMed ID: 27889876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients.
    Triggs EJ; Charles BG; Contin M; Martinelli P; Cortelli P; Riva R; Albani F; Baruzzi A
    Eur J Clin Pharmacol; 1996; 51(1):59-67. PubMed ID: 8880053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Approaches to handling pharmacodynamic baseline responses.
    Dansirikul C; Silber HE; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2008 Jun; 35(3):269-83. PubMed ID: 18446428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats.
    Della Paschoa OE; Mandema JW; Voskuyl RA; Danhof M
    J Pharmacol Exp Ther; 1998 Feb; 284(2):460-6. PubMed ID: 9454785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic-pharmacodynamic modeling of midazolam effects on the human central nervous system.
    Koopmans R; Dingemanse J; Danhof M; Horsten GP; van Boxtel CJ
    Clin Pharmacol Ther; 1988 Jul; 44(1):14-22. PubMed ID: 3391000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients.
    Andrews LM; Hesselink DA; van Schaik RHN; van Gelder T; de Fijter JW; Lloberas N; Elens L; Moes DJAR; de Winter BCM
    Br J Clin Pharmacol; 2019 Mar; 85(3):601-615. PubMed ID: 30552703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility of effect-controlled clinical trials of drugs with pharmacodynamic hysteresis using sparse data.
    Ebling WF; Matsumoto Y; Levy G
    Pharm Res; 1996 Dec; 13(12):1804-10. PubMed ID: 8987075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Temporal linear mode complexity as a surrogate measure of the anesthetic drug effects during sevoflurane anesthesia.
    Choi BM; Koh EH; Kim MG; Kim SH; Ok SY; Noh GJ
    Korean J Anesthesiol; 2013 Nov; 65(5):385-96. PubMed ID: 24363840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.
    Hashimoto Y; Sheiner LB
    J Pharmacokinet Biopharm; 1991 Jun; 19(3):333-53. PubMed ID: 1875286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are plasma concentration values necessary for pharmacodynamic modeling of muscle relaxants?
    Fisher DM; Wright PM
    Anesthesiology; 1997 Mar; 86(3):567-75. PubMed ID: 9066322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rocuronium pharmacodynamic models for published five pharmacokinetic models: age and sex are covariates in pharmacodynamic models.
    Masui K; Ishigaki S; Tomita A; Otake H
    J Anesth; 2018 Oct; 32(5):709-716. PubMed ID: 30099599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Wong FA; Corrado M
    Antimicrob Agents Chemother; 1998 May; 42(5):1098-104. PubMed ID: 9593134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach.
    Rodriguez M; Carlos MA; Ortega I; Suarez E; Calvo R; Lukas JC
    Pharm Res; 2002 Jun; 19(6):858-67. PubMed ID: 12134958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%.
    Knibbe CA; Zuideveld KP; DeJongh J; Kuks PF; Aarts LP; Danhof M
    Clin Pharmacol Ther; 2002 Dec; 72(6):670-84. PubMed ID: 12496748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies?
    Dutta S; Matsumoto Y; Ebling WF
    J Pharm Sci; 1996 Feb; 85(2):232-9. PubMed ID: 8683454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.